URMC / Research / Clinical Trials / Study Details ILYM19167, Reagan, mRNA-2752-P101, Lymphoma, mRNA-2752Research Question:Assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.Basic Study Information Purpose:The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma. Location: University of Rochester Medical CenterStudy Reference #: ILYM19167Lead Researcher (Principal Investigator) Lead Researcher: Patrick Reagan Study Contact InformationStudy Coordinator: Tina BowdishPhone: +1 585-275-9475Email: tina_bowdish@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search